Previous studies have shown that the CC chemokine receptor CCR5 is downregulated on monocyte/macrophage (MO/Mw) surfaces in head and neck squamous cell carcinoma (HNSCC) patients (stage IIIB). Ligands (RANTES, MIP-1a and MIP-1b) of this chemokine receptor were also secreted in lesser quantity from MO/Mw of HNSCC patients in comparison with healthy individuals. In an aim to restore this dysregulated receptor-ligand signaling, we have used neem leaf glycoprotein (NLGP), a novel immunomodulator reported from our laboratory. NLGP upregulated CCR5 expression, as evidenced from studies on MO/Mw of peripheral blood from HNSCC patients as well as healthy individuals. Expression of RANTES, MIP-1a and MIP-1b was also upregulated following NLGP treatment of these cells in vitro. 
INTRODUCTION
Cross-talk between various immune cells such as effector T cells, regulatory T cells, monocytes/macrophages (MO/Mw), dendritic cells, natural killer (NK) cells and others is important for optimal tumor cell killing in the tumor microenvironment.
1,2 Differential trafficking of these cells towards a tumor site for effective immune surveillance is regulated by various chemokines, 3, 4 and in the immunosuppressive state of cancer, chemokine signaling is dysregulated. 5, 6 We have previously demonstrated that defective migration of leukocytes (T cells/NK cells) with high expression of the CXCR3B splice variant is corrected by neem leaf glycoprotein (NLGP). 7 As tumor, tumor microenvironment and tumor secreted factors dictate immune cells to subvert immune system, optimum synchronization of associated immune functions is essential to maximize tumor cell killing. One such function is antigen presentation and positive costimulation, which is mainly performed by antigen presenting cells. These crucial cellular functions are compromised by different negative stimuli in head and neck squamous cell carcinoma (HNSCC) patients, 8, 9 and we hypothesize that their suboptimal function can be modulated by NLGP. 9, 10 In the present communication, we examined the migration of MO/Mw towards tumors by optimal utilization of chemokine signaling to maximize T cell-mediated tumor cell killing. In the migratory process of MO/ Mw, CC chemokines, such as MIP-1a, MIP-1b and RANTES, may play crucial roles through binding to their receptor, CCR5. 11 Although CCR5 is expressed normally in many immune cells, such as lymphocytes, in MO/Mw chemotaxis and in assisting effector T cells to induce tumor cell cytotoxicity. In addition, previous data showing a positive impact of NLGP on macrophage function 9, 17 prompted us to examine the role of NLGP in modulation of CCR5 ligand (RANTES, MIP-1a and MIP-1b) imbalance that may induce successful migration of monocytes towards a tumor. Specifically, we examined the role of chemokine modulation of monocytes by NLGP in the induction of T cell-mediated tumor cell cytotoxicity. For better understanding of the situation, a look on CCR5 and its ligand RANTES on/from oral tumor cells with NLGP treatment was given.
MATERIALS AND METHODS Antibodies
Fluorescence-conjugated antihuman antibodies (CCR5, RANTES, MIP-1a, MIP-1b, CD80, CD86 and human leucocyte antigen (HLA-ABC) and p38mitogen-activated protein kinase (p38MAPK) antibody were procured from BD Pharmingen (San Diego, CA, USA). Mouse antihuman RANTES and antimouse immunoglobulin G were also procured from BD Pharmingen. Neutralizing antibody (antihuman CCR5) was obtained from eBiosciences (San Diego, CA, USA).
Tumor cell lines
Three different oral cancer (KB, SCC131 and SCC084), one colon cancer (COLO205), one T-cell leukemia (Jurkat) and one breast cancer (MCF7) cell lines were originally obtained from the National Center for Cell Sciences (Pune, India). Cells were maintained in DMEM/MEM (Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum, penicillin (50 units/ml) and streptomycin (50 mg/ml) at 37 uC with 5% CO 2 .
NLGP
Neem leaf preparation was prepared by the method described previously. 18 Briefly, matured neem leaves of similar size and color were procured from a standard source, shade dried and pulverized. Neem leaf powder (0.5 mg) was soaked with phosphate-buffered saline (PBS) at pH 7.4 overnight, centrifuged at 1500g and supernatant collected. NLGP was purified from this crude preparation by extensive dialysis against PBS (pH 7.4) and ammonium sulfate precipitation, as described. 7, 19 Finally, NLGP was concentrated with Centricon Membrane Filtration (Millipore Corporation, Bedford, MA, USA) with a 10 kDa molecular weight cut-off. Protein concentration of the purified preparation containing NLGP was measured by Lowry's method using Folin's phenol reagent. 20 Purity of NLGP was confirmed by HPLC before use and a standard NLGP concentration (1.5 mg/ml) was used in most experiments.
HNSCC patients and healthy individuals
Patients (14 males and 8 females) with histopathologically confirmed for HNSCC were included in this study for their informed consent before initiation of any treatment. Healthy individuals of either sex in the same age group were also included in this study as age-matched controls (8 males and 4 females). In addition, three surgical specimens of oral tumors of different origins were collected from three patients who received no treatment. Study design was approved by the institutional ethical committee.
Preparation of MO/Mw
Venous blood was collected from patients and healthy individuals in heparinized tubes and separated on lymphocyte separation medium (MP Biomedicals, Irvine, CA, USA) at 2000g for 30 min. Leukocytes were recovered from the interface, washed, counted and adhered on a plastic surface for 2 h. Adherent cells were checked for CD14 positivity and .90% CD14 1 MO/Mw were used for in vitro assays.
Preparation of tumor cells
A piece of clean oral tumor tissue was minced into small pieces and passed through sterile wire mesh under mild pressure from a syringe piston. After being washed in PBS, cells were maintained in complete RPMI-1640 media. Number and viability of cells were determined microscopically after trypan blue staining.
Purification of CD8
1 T cells CD8 1 T cells were purified using the Magnetic Assisted Cell Sorter (MACS) according to the manufacturer's instruction (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, isolated peripheral blood mononuclear cells (PBMCs) were labeled with biotin-antibody cocktail followed by incubation with avidin-biotin microbeads. The cell suspension was then loaded on a MACS column and allowed to pass through. The effluent was collected as the cell population enriched with CD8
1 T cells. The purity of cells was checked by flow cytometry after labeling with fluorescent-conjugated anti-CD8 antibody, and cell preparations with .90% purity were used for experiments.
Flow cytometry for CCR5, CD80, CD86 and HLA-ABC expression on monocytes Expression of CCR5, CD80, CD86 and HLA-ABC on monocytic surfaces was studied by flow cytometry using the method described earlier. Purified MO/Mw before and after NLGP treatment were washed with fluorescence-activated cell sorting (FACS) buffer and labeled with 20 ml of fluorescence labeled antihuman antibody for 30 min at 4 uC in the dark as per the manufacturer's recommendation (BD Pharmingen, San Diego, CA, USA). After labeling, cells were washed in FACS buffer, fixed in 1% paraformaldehyde in PBS and cytometry was performed using CellQuest software on a FACScan flow cytometer (Becton Dickinson, Mountainview, CA, USA). Suitable negative isotype controls were used to rule out background fluorescence. The data were generated by cytofluorometric analyses of 10 000 events. Percentage of each positive population and mean fluorescence intensity were determined using quadrant statistics.
Flow cytometry for CCR5 expression on oral tumor cells Expression of CCR5 on tumor cell surfaces was also studied by flow cytometry. Following NLGP treatment, tumor cells were stained by the method described above, and cytometry was performed using CellQuest software.
Expression of chemokines
The expression of RANTES, MIP-1a and MIP-1b was analyzed by flow cytometry using the method described earlier. 10 Briefly, purified MO/ Mw were stimulated in vitro with NLGP in the presence of Golgi-Stop (2.0 mM monensin; BD Pharmingen). After fixation and permibilization using cytofix/cytoperm solution (BD Pharmingen), cells were stained for intracellular RANTES, MIP-1a and MIP-1b by incubating with fluorescence-conjugated antibodies for 30 min in the dark at 4 uC. After being washed with 13 Perm/Wash solution, cells were fixed in 1% paraformaldehyde solution and analyzed on a FACSCalibur using CellQuest software. Suitable negative isotype controls were used to rule out background fluorescence. The data were generated by cytofluorometric analyses of 10 000 events. The percentages of positive population and mean fluorescence intensity were determined using quadrant statistics.
Extracellular release of RANTES
The extracellular release of RANTES from MO/Mw and tumor cells from tissue or cell culture was determined by analyzing culture supernatants by ELISA. In brief, 96-well microtiter plates were coated with 100 ml of cell free supernatant, incubated overnight at 4 uC and blocked with 5% bovine serum albumin for 2 h. After washing, primary antibody (mouse antihuman RANTES) at a 1 : 1000 dilution was added to each well and incubated overnight. Washing was performed with PBS with Tween 20. Bound chemokine was detected by staining with peroxidase conjugated secondary antibody (antimouse immunoglobulin G) at a 1 : 500 dilution for 2 h. Color was developed with a tetramethylbenzidine substrate solution. The reaction was stopped with 1 N H 2 SO 4 and absorbance was measured at 450 nm using a microplate reader (Tecan Spectra, Grodig, Austria).
mRNA isolation and reverse transcription-PCR analysis mRNA was isolated from HNSCC patient monocytes and cDNA was synthesized by reverse transcription. Amplification was done by primer specific polymerization. Finally, expression was detected by agarose gel electrophoresis. The oligonucleotide primers of human CCR5 are as follows: CCR5, forward 59-CTG GCC ATC TCT GAC CTG TTT TTC-39 and reverse 59-CAG CCC TGT GCC TCT TCT TCT CAT-39; GAPDH, forward 59-TGT TGC CAT CAA TGA CCC CTT-39 and reverse 59-CTC CAC GAC GTA CTC AGC G-39.
The thermal profile for the PCR reaction was as follows: 95 uC for 30 s, 58 uC for 45 s and 72 uC for 60 s for 30-40 cycles.
Neutralization of CCR5
For neutralization of CCR5, the MO/Mw preparations were incubated with purified antihuman CCR5 antibody (1 mg/ml culture) for 30 min at 4 uC prior to the experiment. After incubation, cells were washed with PBS and the chemotaxis assay was performed. PBMCs were washed and used for flow cytometric analysis and cytotoxicity assays.
Chemotaxis assay
The chemotaxis assay was performed in a Boyden chamber. Briefly, media, chemoattractant and culture supernatant were placed in the lower wells (25 ml/well). A cell suspension (50 ml) at a concentration of 1310 6 cells/ml was added to each well of the upper chamber, which was separated from the lower well by a 5 mm pore size polycarbonate-, polyvinyl-and pyrolidone-free membrane. The chamber was incubated for 90 min at 37uC in 5% CO 2 . The membrane was then carefully removed, washed, fixed in methanol, stained in Giemsa stain (1 : 10 dilution) and mounted on a slide. Cells that migrated and adhered to the lower surface of the membrane were counted using a light microscope. For analysis, five different fields at 340 were observed and the mean value of the cell count was taken.
Transmigration assay
The interaction of monocytes with effector T cells was performed in 24-well (8 mm pore size) polycarbonate cell culture Transwell inserts (Corning Incorporated, Corning, NY, USA). Oral cancer cells (KB) were adhered to the bottom of the culture wells prior to the experiment. Isolated CD8 1 T lymphocytes were cocultured with the oral cancer cells in RPMI-1640 media with different treatments. Purified syngenic MO/Mw cell suspensions (500 ml) in RPMI-1640 media were Restoration of dysregulated CC chemokines in HNSCC by NLGP K Chakraborty et al 398 placed on the inserts and incubated overnight at 37 uC in 5% CO 2 . After incubation, the plate was centrifuged to collect supernatant for the lactate dehydrogenase (LDH) release assay. For migration assays, the inserts were collected, washed in PBS, fixed in methanol and the membrane was stained by Giemsa. Cell migration was quantified using light microscopy to count the number of cells in each field.
Cytotoxicity assay
The cytotoxicity of 72-h-cultured PBMCs against different cancer cells was tested by an LDH release assay using a commercially available Cytotoxicity Detection Kit (Roche Diagnostics, Mannheim, Germany). Briefly, MCF7, KB, COLO205 and Jurkat (1310 4 of each) cells were plated overnight in 96-well flat bottom cell culture plates. The next day, PBMCs (1310 5 ) were added as effectors in each well and cocultured for 4 h. After incubation, the plate was centrifuged for 5 min at 1500g, and cell-free culture supernatant (100 ml) was used to measure the level of released LDH. % Cytotoxicity5(Lysis from effector-Target mixture2Lysis from effector only)2Spontaneous lysis /Maximum lysis2Spontaneous lysis3100.
Immunoblot analysis for p38 MAPK signaling
In vitro stimulated MO/Mw cells were lysed with buffer containing 0.6 M Tris, 2% SDS and 0.9 mM 2-mercaptoethanol. Extracts (20 mg protein) were electrophoresed on 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, blocked with POD-blocking substrate (Roche Diagnostics) and incubated with p38 MAPK antibody (BD Pharmingen) overnight at 4 uC. Equal loading was confirmed by b-actin probing. After washing, blots were incubated with horseradish peroxidase conjugated Restoration of dysregulated CC chemokines in HNSCC by NLGP K Chakraborty et al 400 secondary antibody for 2 h at room temperature. Bands were detected using chemiluminescence (Roche Diagnostics) according to the manufacturer's manual. Band intensity was measured by densitometric scanning.
Statistical analysis
All results represent the average of independent in vitro experiments. The number of experiments is stated in the results section and legends to figures. For all assays, a value represents the mean of three individual observations and is presented as mean6SD. Statistical significance was established by Tukey's test. We compared all pairs of columns using one-way ANOVA with InStat 3 software.
RESULTS

CCR5 expression is suppressed in HNSCC monocytes
As we have previously demonstrated severe immunosuppression 8 and dysregulated CXC chemokine signaling 7, 21 in HNSCC patients, we decided to examine the status of an important CC chemokine receptor in these patients. For this purpose, purified MO/Mw from HNSCC patients (n512) and healthy individuals (n512) were surface-labeled with antihuman CCR5 antibody for flow cytometric analysis. Expression of CCR5 was downregulated in HNSCC patient monocytes when compared with healthy individuals, as shown by flow cytometric (Figure 1a ) and reverse transcription-PCR (Figure 1b) analysis.
Expression of RANTES, MIP-1a and MIP-1b is downregulated in HNSCC patient cells As migration of CCR5 1 cells is predominantly regulated by CCR5 ligands, we assessed the status of these ligands. Specifically, we examined expression of RANTES (n510), MIP-1a (n510) and MIP-1b (n510) in purified MO/Mw from HNSCC patients and healthy individuals by flow cytometric analysis. Expression of RANTES, MIP-1a and MIP-1b was downregulated in HNSCC patient cells when compared with cells from healthy individuals (Figure 2 ). In addition, detection of extracellular release of RANTES from the cells also revealed a similar pattern of downregulation (data not shown). HNSCC monocytes are associated with subnormal chemotactic ability As both CCR5 and its ligands are downregulated in HNSCC, we next examined the migration of MO/Mw in cancer. Freshly isolated monocytes from HNSCC patients (n510) and healthy individuals (n510) were allowed to migrate to a standard chemoattractant. It was observed that the number of migrated monocytes from HNSCC patients was significantly lower than those obtained from healthy individuals (Figure 3) . Neutralization of CCR5 further decreased the migration of monocytic cells (data not shown).
NLGP enhances suppressed CC receptor/ligand expression in HNSCC patient cells
We have previously demonstrated unique immunomodulatory properties of NLGP. Thus, the role of NLGP in modulation of dysregulated CC chemokine signaling was examined here. Purified MO/Mw from HNSCC patients (n512) and healthy individuals (n512) were treated with NLGP for 48 h and assessed for CCR5 expression by flow cytometric analysis. CCR5 expression in HNSCC patient cells was significantly increased after NLGP treatment in 70% of cases (Figure 4a ). mRNA analysis of CCR5 also showed upregulated expression after NLGP treatment (Figure 4b ). In addition, we found that expression of the chemokines RANTES, MIP-1a and MIP-1b from HNSCC (n56) and healthy (n56) monocytes was induced by NLGP treatment (Figure 5a ). Finally, analysis of NLGP-treated monocyte culture supernatants by ELISA demonstrated an approximately two fold increase in extracellular release of RANTES when compared with the supernatant from the untreated culture (Figure 5b ).
NLGP does not alter CCR5 expression or RANTES secretion from oral tumor cells Our data show that there is increased CC receptor/ligand expression in HNSCC monocytes as compared to healthy controls. Thus, we Restoration of dysregulated CC chemokines in HNSCC by NLGP K Chakraborty et al 402 examined the effect of NLGP on CCR5 expression and secretion of its ligand RANTES in tumor cells. To this end, tumor cells from surgically removed oral tumor tissues (n53) and tumor cell lines (n53) were cultured in the presence of NLGP for 48 h. Expression of CCR5 on the tumor cell surface and RANTES secretion in culture supernatant were assessed. As presented in Figure 6 and Table 1 , NLGP had negligible effect on either CCR5 expression or RANTES secretion from oral tumor cells.
NLGP efficiently enhances the migratory ability of HNSCC monocytes As we have observed poor chemotaxis of monocytes from HNSCC patients, we wanted to determine whether NLGP could enhance monocyte migration. Purified MO/Mw from HNSCC patients (n56) were allowed to migrate in the presence of supernatant from an NLGP-stimulated PBMC culture or control (NLGP-Sup versus PBS-Sup). We found that migration of monocytes to the NLGP-Sup was greater than to control PBS-Sup (Figure 7a) . Additionally, HNSCC monocytes were cultured for 48 h with NLGP, and chemotaxis of these monocytes to a standard chemoattractant was tested (n56). HNSCC monocytes after NLGP treatment (1.5 mg/ml) showed significantly greater migratory activity than the PBS-treated control cells (Figure 7b ). Similar enhancement was also noted with healthy monocytes (data not shown). Taken together, these results show that NLGP may be able to restore monocyte trafficking by regulating expression of both the CCR5 receptor and its ligands. 
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In order to elucidate the role of CCR5 in NLGP-enhanced migration, monocytes from HNSCC patients (n56) were stimulated with NLGP in the presence of a CCR5-neutralizing antibody and were allowed to migrate to a standard chemoattractant. We found that CCR5 neutralization on the monocyte surface reduces monocyte migration (Figure 7c ), demonstrating that NLGP increases monocyte migration through upregulation of CCR5.
NLGP-induced monocyte chemotaxis is partially dependent on p38 MAPK
Several studies previously demonstrated a critical role for p38 MAPK in the upregulation of CCR5 expression and monocyte migration. 22 In addition, we have also observed p38 MAPK activation in monocytes after NLGP treatment. 9 Thus, we examined p38 MAPK activation in monocyte signaling to determine whether it was involved in NLGP-induced CCR5-dependent monocyte chemotaxis. To this end, purified MO/Mw from HNSCC patients (n53) and healthy individuals (n53) were treated with NLGP for 4 h and western blot analysis was performed with cellular lysates. Expression of p38 MAPK in HNSCC monocytes was upregulated following NLGP treatment (Figure 8a ). To further confirm this observation, we used SB203580, a specific inhibitor for p38 MAPK activation. Treatment by the inhibitor SB203580 significantly reduced the number of migrated monocytes (Figure 8b ). SB203580 also downregulated CCR5 expression on monocyte surfaces after stimulation with NLGP (data not shown).
NLGP upregulates costimulatory molecules on CCR5
1 monocytes
NLGP-induced CCR5
1 -migrating monocytes may cross-talk with T cells to enhance tumor cell cytotoxicity. As several costimulatory molecules on the surface of monocytes may participate in this crosstalk, we examined expression of CD80, CD86 and HLA-ABC on the surface of CCR5 1 monocytes from HNSCC patients (n56) and healthy individuals (n56) after NLGP treatment for 48 h. We found that NLGP upregulates CD80
1 and HLA-ABC 1 on CCR5 1 monocytes, but does not alter CD86 1 (Figure 9 ).
NLGP restores the cytotoxicity of HNSCC-PBMCs towards cancer cells
We hypothesized that migrating monocytes participate in the induction of T-cell cytotoxicity. To test this, PBMCs obtained from either HNSCC patients (n56) or healthy individuals (n56) were cultured for 5 days in the presence of NLGP. Cells were then incubated with the cancer cell lines KB (oral), MCF7 (breast), COLO-205 (colon) and Jurkat (T lymphoblast) to assess their ability to induce cytotoxicity. Figure 10 shows that the stimulation of PBMCs with NLGP significantly enhances their cytotoxicity to cancer cells.
The interaction between NLGP-treated monocytes and effector T cells is crucial for cancer cell cytotoxicity
Our data suggest that NLGP treatment induced enhanced migration of monocytes due to modulation of chemokine signaling. In addition, we showed that this enhanced migration can improve tumor cytotoxicity by PBMCs. To elucidate the role of monocytes in T-cell cytotoxicity, we performed an experiment as detailed in Figure 11 (cartoon). Oral cancer (KB) cells were cocultured with purified T cells and monocytes (either NLGP treated or CCR5 neutralized) from the same donor. The cells were allowed to migrate to the bottom of a well through pores in culture inserts. After overnight incubation, migrated cells were counted on membranes (Figure 11a ) and the culture supernatant was assayed by the LDH release assay. We found that the presence of monocytes affects the cytotoxic efficacy of T lymphocytes, as we observed that the T cells kill the cancer cells more efficiently in the presence of syngenic monocytes (Figure 11b ). NLGP-treated monocytes migrated more (Figure 11a ) and induced a greater cytotoxicity by T cells (Figure 11b ). Neutralization of CCR5 hindered migratory ability, which affects interaction with T lymphocytes and ultimately resulted in impaired cancer cell killing ( Figure 11) . Repetition of the experiment generated identical data. Restoration of dysregulated CC chemokines in HNSCC by NLGP K Chakraborty et al 404
DISCUSSION
The present study was undertaken in order to better understand the significance of monocyte chemotaxis in immune-mediated eradication of tumor cells. Monocyte chemotaxis is driven by several chemokines, but the current study focused on the CC chemokines RANTES, MIP-1a and MIP-1b. All of these chemokines transduce signals through the CCR5 receptor. The biological activity of chemokines is transduced through high affinity binding of ligands with their receptors; thus, proper expression of these molecules is very important for function. We have previously reported severe immunosuppression in patients suffering from stage IIIB HNSCC. 8 Selection of HNSCC stage IIIB is due to the frequent reporting of these patients in our clinic. We also demonstrated a defect in CXC chemokine signaling in lymphocytes from HNSCC patients. 7, 21 Interestingly, our current study demonstrated partial restoration of lymphocyte chemotaxis and cytotoxicity after cellular treatment with NLGP. 7, 10, 23 In vivo, T lymphocytes alone cannot kill the tumor cells; thus, cooperation with other cellular components is essential for optimal killing. Antigen presenting MO/Mw have a significant role in controlling T cell-mediated tumor cell killing. As it is difficult to obtain resident macrophages from the tumor microenvironment, circulating monocytes from HNSCC patients were used in the present study. CCR5 and its ligands play crucial roles in the regulation of intratumoral M1 macrophage accumulation and subsequent induction of antitumor immunity. Evaluation of CCR5 expression on the surface of purified MO/Mw revealed a significant downregulation in HNSCC patient cells. In addition, a significant decrease in the secretion of associated chemokines was observed. Decreased expression of CCR5 in monocytes from HNSCC patients was reported, 24 which is associated with upregulated cyclooxygenase-2 and prostaglandin. Contrary to the monocytes, oral cancer cells, especially those with high invasiveness, express CCR5 on their surface that regulates increased migration of tumor cells and metastasis. 25 In agreement with this report, we have also detected CCR5 expression on the surface of oral tumor cells obtained from oral cancer tissue and cell lines. This differential CCR5 expression in immune cells versus tumor cells seems to be associated with suboptimal circulation of immune cells towards a chemotactic gradient from the tumor site. Proper expression of CCR5 and an optimal chemotactic gradient of CCR5 ligands are prerequisites for the accumulation of host-protective M1 MO/Mw at a tumor site. As such, dyseregulation of receptor or ligand expression can affect MO/Mw-mediated innate and adoptive immune responses against cancer. This could also cause impaired macrophage assistance to cytotoxic T lymphocytes for killing of tumor cells. Thus, CCR5 signaling needs to be optimized by activated immune cells for tumor cell lysis.
In order to further study the role of NLGP in restoring several immune dysfunctions, 7, 9, 26 we evaluated the regulatory role of this immunomodulator on dysregulated CCR5 signaling in HNSCC patient cells. This study is particularly relevant because of a report on CXC chemokines in HNSCC, 7 in which a positive role for NLGP was demonstrated. In vitro treatment of HNSCC monocytes with NLGP upregulated expression of CCR5 at both the protein and mRNA levels. Interestingly, in healthy monocytes, no significant effect of NLGP was observed. This observation suggests that NLGP induces CCR5 expression only in the cancer-associated CCR5-downregulated state. Establishment of specific antitumor immunity requires T-helper type 1 cytokines in the microenvironment, where interferon (IFN)-c directs M1 macrophage costimulation and antigen presentation. NLGP has been previously reported to be a strong inducer of IFNc, 10 and here we observed that NLGP-dependent upregulation of CCR5 expression on monocyte surfaces is regulated by IFN-c. In addition, we also observed that neutralization of IFN-c in the presence of NLGP significantly downregulates CCR5 expression (data not shown). The expression of the chemokines RANTES, MIP-1a and MIP-1b in HNSCC patient monocytes was also upregulated after Restoration of CC chemokine receptor-ligand signaling was also reflected in the migration of monocytes. Monocyte chemotaxis was assayed by two different experiments. First, normal PBMCs were stimulated with NLGP and the supernatant was used as a chemoattractant. Results of this study demonstrated higher migration of monocytes maintained in NLGP-conditioned media from both HNSCC patients and healthy individuals. Second, HNSCC and healthy monocytes were stimulated with NLGP before a migration assay. In these experiments, better migration was observed when cells were stimulated with NLGP. These observations suggest that NLGP could enhance chemotaxis by either functional activation of CCR5 1 HNSCC monocytes or by enhancing the release of RANTES, MIP-1a and MIP-1b. The role of CCR5 in this chemotactic process was confirmed by neutralization of CCR5, which resulted in inhibition of monocyte chemotaxis. As we observed successful chemotaxis of monocytes from HNSCC patients with NLGP treatment, we questioned the mechanism of action of the induction of antitumor immunity. MO/Mw may directly impart their tumoricidal functions, or they may act as antigen presenting cells to promote T-cell cytotoxicity. There is a possibility that NLGP-treated monocytes kill tumor cells directly. Although this possibility is not explicitly addressed here, we have previously reported that NLGP-activated monocytes are cytotoxic to tumor cells. 9 Upregulation of the costimulatory molecules CD80 and HLA-ABC on CCR5
1 cells suggests better cooperation of monocytes for T-cell functions. Previously, it was reported that NLGP is a strong inducer of IL-12p70 from monocytes through the p38 MAPK pathway. Here, we show that p38 MAPK was upregulated in CCR5
1 monocytes from HNSCC patients after immunomodulation with NLGP. In addition, blocking of p38 MAPK by the specific inhibitor SB203580 abrogated monocyte migration. Although no studies have shown a role for p38 MAPK in monocyte migration, its role in the chemotaxis of other cell types has been reported. Scaldaferri et al. 22 assessed the functional role of p38 MAPK in the regulation of lymphocyte adhesion to and chemotaxis across the microvasculature in inflammatory bowel disease. Tumor-necrosis factor-a-primed neutrophils migrate utilizing signals through CCR5 that involves various kinases, including p38 MAPK. 27 Soluble vascular cell adhesion molecule-1-induced eosinophil migration is dependent on p38 MAPK 28 . Further studies are needed to understand the mechanism of If we hypothesize that impaired migration of lymphocytes/monocytes is restored by NLGP-induced homing to the tumor microenvironment, it is important to understand whether these migrated cells can efficiently eradicate tumor cells. The cytotoxicity of PBMCs obtained from HNSCC patients is significantly reduced in comparison with PBMCs from healthy individuals. 8 To test whether NLGP could restore their cytotoxicity, cells were incubated with NLGP and cocultured with tumor cells of various origins. Results of these studies clearly suggest that NLGP can enhance the cytotoxicity of these immune cells. The importance of monocyte chemotaxis in this cytotoxic process was shown indirectly by neutralizing the chemokine receptor under study, CCR5. Cytotoxicity was significantly impaired after neutralization of CCR5.
Using transwell assays, we have further demonstrated the involvement of NLGP-induced CCR5 1 monocytes in the cytotoxic process. Cytotoxicity of monocytes was significantly increased following immunomodulation of macrophages by NLGP. This observation suggests that NLGP-mediated CCR5-dependent signals from monocytes are transduced to lymphocytes in a contact-independent manner, which is reflected in the enhanced killing of tumor cells.
In conclusion, NLGP-mediated restoration of CCR5 chemokine signaling on monocytes could be a new immunotherapeutic strategy for the treatment of cancer. This immune modulation by NLGP could be an effective tool as a therapeutic vaccine. Further, in vivo studies are in progress for complete understanding of chemokine signaling in tumors. Restoration of dysregulated CC chemokines in HNSCC by NLGP K Chakraborty et al 407
